| Date | Title | Description |
| 22.07.2025 | Omega Funds: $647 Million Fund VIII Closed To Invest In Life Science Companies | Global healthcare venture capital firm Omega Funds has closed its eighth fund at $647 million, surpassing its initial target of $600 million. The oversubscribed Omega Fund VIII, L.P., received backing from both new and existing investors. I... |
| 16.06.2025 | Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241 | PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC")
CASTRES, France, June 16, 2025... |
| 15.01.2025 | Eli Lilly купит у Scorpion Therapeutics программу по производству лекарств за $2,5 млрд | В понедельник производитель лекарств Eli Lilly заявил, что приобретает Scorpion и ее программу STX-478, при этом акционеры частной компании получат до $2,5 млрд в качестве аванса, а последующие выплаты будут зависеть от достижения контрольн... |
| 13.01.2025 | Lilly to Acquire Scorpion Therapeutics’ Mutant-Selective PI3Kα Inhibitor Program | - |
| 13.01.2025 | Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B | - |
| 08.10.2024 | Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended To Treat Locally Advanced or Met... | PFL-241/STX-241 is a highly selective, and potentially best-in-class fourth generation epidermal growth factor receptor ("EGFR") inhibitor
One of two EGFR programs being developed with Scorpion Therapeutics
CASTRES, France and BOS... |
| 14.08.2024 | The Pulse of Investment: July's Landscape in U.S. Venture Capital | July 2024 was a month of simmering activity in the U.S. venture capital scene. The heat of summer didn’t deter investors, but it did reveal a stark contrast in engagement levels among the major players. While some firms basked in the sun of... |
| 12.08.2024 | Most-Active US Investors In July: Andreessen Horowitz Led Cool Month | 5 Shares Email Facebook Twitter LinkedIn
This is a monthly feature that runs down some of the most-active investors in U.S.-based companies, looks at some of their most interesting investments, and includes some odds and ends of who spent w... |
| 29.07.2024 | Scorpion Therapeutics: A Bold Leap in Precision Oncology | Scorpion Therapeutics is making waves in the world of cancer treatment. With a recent $150 million Series C funding round, the Boston-based biotech is poised to redefine the landscape of precision oncology. This funding is not just a financ... |
| 27.07.2024 | Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline | Scorpion Therapeutics, a clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, announced the closing of a $150 million Series C financing. The funding was co... |
| 19.07.2024 | The Week’s 10 Biggest Funding Rounds: Cardurion Pharmaceuticals And Human Interest Nab Largest Raises | 5 Shares Email Facebook Twitter LinkedIn
Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board.
This is a w... |
| 16.07.2024 | Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline | As it broadens the clinical ambitions for its small molecule oncology programs, Scorpion Therapeutics has secured $150 million in financial fuel.
The Boston-based biotech applies its drug-hunting platform to validated oncogenes to create sm... |
| 16.07.2024 | Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline | - |
| 16.07.2024 | Scorpion Therapeutics Raises $150M in Series C Financing | Scorpion Therapeutics, a Boston, MA-based clinical-stage oncology company, raised $150M in Series C funding.
The round was led by Frazier Life Sciences and Lightspeed Venture Partners, and included additional new support from Willet Advisor... |
| 10.10.2023 | Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced... | -- STX-721 is characterized by high selectivity and a potentially best-in-class profile --
-- Scorpion's second program to enter clinical development this year --
-- One of two EGFR programs being developed with Pierre Fabre Laboratories --... |
| 08.01.2021 | Daily funding roundup - January 8th, 2021 | SilviaTerra raised $4.4M; Hipcamp landed $57M; DiCE Molecules secured $80M; Affinivax picks up $226M
SilviaTerra: SilviaTerra is a San Francisco-based forestry company for organizations to exchange carbon offsets. SilviaTerra has raised $4.... |
| 08.01.2021 | Armed with $270M in capital, Scorpion Therapeutics aims to broaden the reach of precision oncology | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| 07.01.2021 | Congratulations Gary Glick, CEO and the Scorpion Therapeutics team on an oversubscribed $162 million Series B financing | - |
| 07.01.2021 | Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing | Scorpion Therapeutics, Inc., a next-generation precision oncology company, today announced the closing of an oversubscribed Series B financing, which raised $162 million. The financing was led by Boxer Capital of Tavistock Group, EcoR1 Capi... |
| 07.01.2021 | Three months after launch, precision medicine startup Scorpion Therapeutics raises $162M | Less than three months after publicly launching, Scorpion Therapeutics, a cancer-focused precision medicine startup founded by serial biotech entrepreneur Gary Glick, has brought in $162 million in an oversubscribed Series B round.
The roun... |
| 07.01.2021 | Scorpion Therapeutics strikes major $162M funding round for 'precision oncology 2.0'
W h i t e p a p e r
Weighing the Costs: | Less than three months after breaking cover with an impressive $102 million series A, Scorpion has whipped up another major funding round, nabbing $162 million for its next-gen cancer drugs.
Sponsored by Agilent Technologies
How would you l... |
| 07.01.2021 | Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing | - |
| 07.01.2021 | Scorpion Therapeutics, Inc. announced that it has received $161.999991 million in funding from a group of investors | On January 7, 2021, Scorpion Therapeutics, Inc. closed the transaction. The company has received $15,000,014.493976 in its second tranche bringing the total funds raised in the transaction to $161,999,991.493976. The transaction was co-led ... |
| 07.01.2021 | Scorpion Therapeutics strikes major $162M funding round for 'precision oncology 2.0' | Less than three months after breaking cover with an impressive $102 million series A, Scorpion has whipped up another major funding round, nabbing $162 million for its next-gen cancer drugs.
The oversubscribed financing was led by some big ... |
| 07.01.2021 | Scorpion Therapeutics Raises $162M In Series B | BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc., a next-generation precision oncology company, today announced the closing of an oversubscribed Series B financing, which raised $162 million. The financing was led by Boxer Capital of Ta... |
| 01.01.2021 | SCORPION THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $162 MILLION SERIES B FINANCING | - |
| 29.10.2020 | Scorpion Therapeutics Raises $108M in Funding | Scorpion Therapeutics, Inc., a Boston, MA-based next-generation precision oncology company, closed a $108m Series A financing.
The round was led by Atlas Venture, Omega Funds, and Vida Ventures, with participation from Abingworth and Partne... |
| 26.10.2020 | Scorpion Therapeutics Launches with $108M |
BOSTON, MA, Scorpion Therapeutics announced the closing of a $108 million Series A financing, led by Atlas Venture, Omega Funds, and Vida Ventures.
>> Click here for more funding data on Scorpion Therapeutics
>> To export Sc... |
| 26.10.2020 | Scorpion Therapeutics Launches with $108 Million to Advance Precision Oncology 2.0 | - |
| 26.10.2020 | Scorpion Therapeutics Launches with $108 Million | BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc., a next-generation precision oncology company, today announced the closing of a $108 million Series A financing, led by Atlas Venture, Omega Funds, and Vida Ventures, with participation f... |
| - | Armed with $270M in capital, Scorpion Therapeutics aims to broaden the reach of precision oncology | A startup aspiring to widen the pool of patients benefiting from precision oncology has raised $270 million from investors since its founding in early 2020.
The total includes $162 million from a Series B financing announced this week by th... |
| - | Scorpion Therapeutics | “We are developing drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to improve their safety and efficacy.” |
| - | Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs | Tyler Le/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Insider asked 12 venture capitalists which biotech startups would take off in the next 12 months.
Here are the 23 companie... |
| - | 10 Boston-area biotechs that VCs say are poised to take off in the next year | Skyline of Boston, Massachusetts. Getty Images. This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Insider asked 12 venture capitalists which biotech startups would take off in the next year... |
